- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/56 - Amides
Patent holdings for IPC class C07D 213/56
Total number of patents in this class: 776
10-year publication summary
|
36
|
66
|
64
|
58
|
43
|
42
|
56
|
36
|
40
|
11
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4789 |
19 |
| Corteva Agriscience LLC | 2648 |
17 |
| Atnx Spv, LLC | 34 |
15 |
| Gilead Sciences, Inc. | 2207 |
14 |
| Takeda Pharmaceutical Company Limited | 2718 |
11 |
| Neurocrine Biosciences, Inc. | 445 |
10 |
| Purdue Pharma L.P. | 492 |
9 |
| ACADIA Pharmaceuticals Inc. | 194 |
8 |
| The Salk Institute for Biological Studies | 452 |
8 |
| Theravance Biopharma R&D IP, LLC | 416 |
8 |
| Merck Sharp & Dohme LLC | 3737 |
8 |
| F. Hoffmann-La Roche AG | 7847 |
7 |
| Bayer Pharma AG | 1025 |
7 |
| CHDI Foundation, Inc. | 106 |
7 |
| Nihon Nohyaku Co., Ltd. | 326 |
7 |
| Ono Pharmaceutical Co., Ltd. | 419 |
7 |
| Tetra Discovery Partners, LLC | 11 |
7 |
| Vectus Biosystems Limited | 28 |
7 |
| Hoffmann-La Roche Inc. | 3726 |
6 |
| Merck Patent GmbH | 5669 |
6 |
| Other owners | 588 |